Literature DB >> 2876452

Neuroleptic reduction of cocaine-induced paranoia but not euphoria?

F H Gawin.   

Abstract

Central dopaminergic activation is hypothesized to underly schizophrenia and, paradoxically, stimulant euphoria. Four cocaine abusers with histories of stimulant-induced paranoid psychoses reported selective reduction in psychotic symptoms but not euphoria when treated with dopamine blockers. This provides preliminary evidence against efficacy of neuroleptics in cocaine abuse prevention, and suggests euphoria and paranoia may have discriminable neurophysiological substrates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876452     DOI: 10.1007/bf00172886

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  4 in total

1.  Assault and homicide associated with amphetamine abuse.

Authors:  E H Ellinwood
Journal:  Am J Psychiatry       Date:  1971-03       Impact factor: 18.112

2.  Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine.

Authors:  H De Wit; R A Wise
Journal:  Can J Psychol       Date:  1977-12

Review 3.  Neural mechanisms of the reinforcing action of cocaine.

Authors:  R A Wise
Journal:  NIDA Res Monogr       Date:  1984

4.  Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of MAO inhibitors: a possible role for beta-phenylethylamine in the cocaine cue.

Authors:  F C Colpaert; C J Niemegeers; P A Janssen
Journal:  Pharmacol Biochem Behav       Date:  1980-10       Impact factor: 3.533

  4 in total
  25 in total

1.  Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.

Authors:  Paul W Czoty; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 2.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

3.  The role of peripheral and central sodium channels in mediating brain temperature fluctuations induced by intravenous cocaine.

Authors:  Eugene A Kiyatkin; P Leon Brown
Journal:  Brain Res       Date:  2006-09-07       Impact factor: 3.252

Review 4.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 5.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 6.  William L. Woolverton: a case history in unraveling the behavioral pharmacology of stimulants.

Authors:  Michael A Nader; Robert L Balster; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

7.  Differential antagonism of cocaine self-administration and cocaine-induced disruptions of learning by haloperidol in rhesus monkeys.

Authors:  Peter J Winsauer; Joseph M Moerschbaecher; Alison M Roussell
Journal:  J Exp Anal Behav       Date:  2008-03       Impact factor: 2.468

Review 8.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 9.  Animal models of drug craving.

Authors:  A Markou; F Weiss; L H Gold; S B Caine; G Schulteis; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Relationship between psychostimulant-induced "high" and dopamine transporter occupancy.

Authors:  N D Volkow; G J Wang; J S Fowler; S J Gatley; Y S Ding; J Logan; S L Dewey; R Hitzemann; J Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.